

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet 2 of 3

Application Number 10/798,470
 Filing Date 03/11/2004
 First Named Inventor Teitelbaum
 Art Unit 1614
 Examiner Name P.G. Spivack
 Attorney Docket Number UM-08764

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published:	T ²
	9	Kirsner, J. B., et al. (eds), Inflammatory Bowel Disease, 3rd ed., Lea and Febiger, Philadelphia (1988). This is a book and is not being supplied at this time.	
	10	Zipser, R. D., (ed.), Dig. Dis. Sci., 33 Suppl.:1S-87S (1988)	
PS	11	Schappi et al., Arch. Dis. Child., 1984:147 (2001).	
PS	12	Noguchi et al., Jap. J. Pharmacol. 40(3):373-80 (1986) .	
PS	13	Nussberger et al., J. Cardiovasc. Pharmacol. 9(1):39-44 (1987) ,	
PS	14	Attwood, et al., FEBS Lett. 165(2):201-6 (1984).	
PS	15	Takata et al., Clin. Exp. Pharmacol. Physiol. 10:131 (1983) .	
	16	Acta. Pharmacol. Toxicol. 59 (Supp. 5):1:224 (1986) (No Authors Listed) (This reference is not being supplied at this time)	
	17	Acta. Pharmacol. Toxicol. 59 (Supp. 5):2:342 (1986) (No Authors Listed) (This reference is not being supplied at this time)	
PS	18	Sybertz et al., J. Cardiovasc. Pharmacol. 5(4):643, 655 (1983).	

Examiner Signature	Phyllis Spivack	Date Considered	7/15/06
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,470
Filing Date	03/11/2004
First Named Inventor	Teitelbaum
Art Unit	1614
Examiner Name	P.G. Spivack
Attorney Docket Number	UM-08764

Sheet 3

of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PS	19	Lees, Eur. J. Clin. Pharmacol. 31(5):519-24 (1987).	
PS	20	Kim et al., J. Med. Chem. 26:394 (1983).	
PS	21	Baum et al., J. Cardiovasc. Pharmacol. 5(4):655 (1983).	

Examiner Signature	<i>Phillip Spivack</i>	Date Considered	7/15/06
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.